Voyager Therapeutics Inc. (NASDAQ: VYGR)’s stock price has gone decline by -8.79 in comparison to its previous close of 13.09, however, the company has experienced a -2.69% decrease in its stock price over the last five trading days.
Is It Worth Investing in Voyager Therapeutics Inc. (NASDAQ: VYGR) Right Now?
Voyager Therapeutics Inc. (NASDAQ: VYGR) has a higher price-to-earnings ratio of 5.21x compared to its average ratio. compared to its average ratio and a 36-month beta value of 1.02. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
The average price point forecasted by analysts for Voyager Therapeutics Inc. (VYGR) is $13.67, which is $1.73 above the current market price. The public float for VYGR is 32.93M, and currently, short sellers hold a 3.34% ratio of that float. The average trading volume of VYGR on May 26, 2023 was 454.66K shares.
VYGR’s Market Performance
VYGR stock saw an increase of -2.69% in the past week, with a monthly gain of 60.48% and a quarterly increase of 68.41%. The volatility ratio for the week is 10.53%, and the volatility levels for the last 30 days are 9.39% for Voyager Therapeutics Inc. (VYGR). The simple moving average for the past 20 days is 19.33% for VYGR’s stock, with a 67.98% simple moving average for the past 200 days.
VYGR Trading at 37.84% from the 50-Day Moving Average
After a stumble in the market that brought VYGR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.74% of loss for the given period.
Volatility was left at 9.39%, however, over the last 30 days, the volatility rate increased by 10.53%, as shares surge +64.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +48.88% upper at present.
During the last 5 trading sessions, VYGR fell by -2.69%, which changed the moving average for the period of 200-days by +95.42% in comparison to the 20-day moving average, which settled at $10.24. In addition, Voyager Therapeutics Inc. saw 95.74% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VYGR starting from Sandrock Alfred, who sale 7,437 shares at the price of $7.83 back on Apr 03. After this action, Sandrock Alfred now owns 214,618 shares of Voyager Therapeutics Inc., valued at $58,232 using the latest closing price.
Swartz Robin, the Chief Operating Officer of Voyager Therapeutics Inc., sale 1,259 shares at $7.83 during a trade that took place back on Apr 03, which means that Swartz Robin is holding 71,617 shares at $9,858 based on the most recent closing price.
Stock Fundamentals for VYGR
Current profitability levels for the company are sitting at:
- -189.81 for the present operating margin
The net margin for Voyager Therapeutics Inc. stands at -190.29. The total capital return value is set at -41.63, while invested capital returns managed to touch -42.97.
Based on Voyager Therapeutics Inc. (VYGR), the company’s capital structure generated 46.48 points at debt to equity in total, while total debt to capital is 31.73. Total debt to assets is 22.79, with long-term debt to equity ratio resting at 40.62. Finally, the long-term debt to capital ratio is 27.73.
When we switch over and look at the enterprise to sales, we see a ratio of 6.83, with the company’s debt to enterprise value settled at 3.22. The receivables turnover for the company is 8.45 and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.68.
Conclusion
To put it simply, Voyager Therapeutics Inc. (VYGR) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
